PTK2 and cancer: This review highlights the current trends in FAK research, focusing on its implications in cancer progression and the latest developments in several FAK-targeting molecules, including defactinib, VS-4718, BI-853520, and GSK2256098, that are progressing through various clinical and preclinical stages, for therapeutic applications.